AI Article Synopsis
Article Abstract
Purpose: Immunoglobulin (Ig) replacement therapy is an important life-saving treatment modality for patients with primary antibody immune deficiency disorders (PAD). IVIG and SCIg are suitable alternatives to treat patients with PAD but vary in key ways. Existing evidence on patient preferences for Ig treatments given the complexities associated with IVIG and SCIg treatment is limited and fails to account for variations in preferences across patients. For this reason, we sought to evaluate PAD patient preferences for features of IVIG and SCIg across different patient characteristics.
Materials And Methods: 119 PAD patients completed a discrete-choice experiment (DCE) survey. The DCE asked respondents to make choices between carefully constructed treatment alternatives described in terms of generic treatment features. Choices from the DCE were analyzed to determine the relative influence of attribute changes on treatment preferences. We used subgroup analysis to evaluate systematic variations in preferences by patients' age, gender, time since diagnosis, and treatment experience.
Results: Patients were primarily concerned about the duration of treatment side effects, but preferences were heterogeneous. This was particularly true around administration features. Time since diagnosis was associated with an increase in patients' concerns with the number of needles required per infusion. Also, patients appear to prefer the kind of therapy they are currently using which could be the result of properly aligned patient preferences or evidence of patient adaptive behavior.
Conclusions: Heterogeneity in preferences for Ig replacement treatments suggests that a formal shared decision making process could have an important role in improving patient care.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854788 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.827305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Customizing subcutaneous immunoglobulin administration in primary antibody deficiency: patient-centric care perspectives.
Immunotherapy
December 2024
Division of Basic and Clinical Immunology, University of California, Irvine, CA, USA.
This report delves into the challenges and potential solutions associated with flexible, customized subcutaneous immunoglobulin (SCIG) infusion regimens for patients with primary antibody deficiency disease (PAD). Advances in the treatment of inborn errors of immunity, particularly PAD, have converted fatal diseases into chronic, complex, long-term conditions that make adherence to treatment a critical issue. Conventional SCIG infusion regimens, while clinically effective, may not always align with the varied lifestyles, changing lifestyles and commitments of patients which can lead to missed doses, diminishing adherence thus posing potential health risks and compromising the overall effectiveness of treatment.
View Article and Find Full Text PDFPurpose: Multifocal motor neuropathy (MMN) is a rare immune-mediated neuropathy causing progressive, asymmetric weakness without sensory loss. Long-term administration of intravenous (IVIg) or subcutaneous (SCIg) immunoglobulins is the primary therapeutic approach. Despite this, therapy failure can result in a decline in strength, particularly in the hands, impacting daily activities.
View Article and Find Full Text PDFInfusion parameters, safety, and practical guidance for the manual administration of subcutaneous immunoglobulin 20% (Ig20Gly).
Allergy Asthma Clin Immunol
October 2024
Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Article Synopsis
- Primary immunodeficiency diseases (PIDs) are genetic immune system disorders requiring lifelong immunoglobulin replacement therapy, usually delivered through IVIG or SCIG infusions.
- Ig20Gly, a 20% immune globulin solution, is a replacement therapy approved for various age groups, with recent approvals for manual administration in Europe aimed at simplifying the process.
- Manual administration of Ig20Gly allows for faster infusion rates, similar safety and satisfaction levels compared to infusion pumps, and potential cost savings for healthcare systems due to lower equipment and nursing needs.
Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies.
Immunotherapy
October 2024
Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA.
Article Synopsis
- - Immunoglobulin G (IgG) dosing for primary immunodeficiency diseases (PIDs) is personalized, taking into account individual patient experiences, clinical status, and physician input.
- - Regular monitoring of serum IgG levels is crucial for both diagnosing PIDs and adjusting IgG treatment plans, and this process should not be done alone but as part of a broader care strategy.
- - The review explores current and future IgG dosing strategies, considering distinct patient groups, such as those new to immunoglobulin therapy and those transitioning between intravenous (IVIG) and subcutaneous (SCIG) administration.
Quality of life in primary immunodeficiency: Its contribution to shared decision-making and patient outcomes.
Allergy Asthma Proc
September 2024
Quality of life (QOL) measures have become increasingly important in the management of patients with complex diseases. There are a number of instruments to measure QOL that include broad areas or domains of physical, psychological, social, spiritual, and environmental issues. The number of potential domains plus the large number of items within each domain have led to the development of a large variety of QOL instruments and of different approaches by using both health-related and non-health-related factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!